STOCK TITAN
  1. Home
  2. News
  3. ENTA

Enanta Pharmaceuticals Inc - ENTA STOCK NEWS

Welcome to our dedicated news page for Enanta Pharmaceuticals (Ticker: ENTA), a resource for investors and traders seeking the latest updates and insights on Enanta Pharmaceuticals.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Enanta Pharmaceuticals's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Enanta Pharmaceuticals's position in the market.

News
Enanta Pharmaceuticals Announces Data Presentation at ESCMID Global 2024
Rhea-AI Summary
Enanta Pharmaceuticals announced that data from the SPRINT study of EDP-235 has been accepted for presentation at ESCMID Global 2024. The study focused on the efficacy and safety of EDP-235 in non-hospitalized adults with mild or moderate COVID-19. The poster presentation will include primary and post-hoc analyses from the Phase 2 clinical trial.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-8.85%
Tags
none
-
News
Enanta Pharmaceuticals to Participate at Leerink Partners Global Biopharma Conference
Rhea-AI Summary
Enanta Pharmaceuticals, Inc. announced participation in a fireside chat at Leerink Partners Global Biopharma Conference. The event will feature the company's President and CEO, Jay R. Luly, and Chief Product Strategy Officer, Tara L. Kieffer. The webcast will be available on Enanta's website.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.98%
Tags
conferences
-
News
Enanta Pharmaceuticals Reports Financial Results for its Fiscal First Quarter Ended December 31, 2023 with Webcast and Conference Call Today at 4:30 p.m. ET
Rhea-AI Summary
Enanta Pharmaceuticals, Inc. reported financial results for its fiscal first quarter ended December 31, 2023, with total revenue of $18.0 million. The company aims to announce topline data for RSVPEDs and EDP-323 challenge study in Q3 2024. They also expanded into immunology with a new discovery program of oral KIT inhibitors for Chronic Spontaneous Urticaria, targeting a development candidate selection in 2024. Cash and Marketable Securities totaled $337.2 million at December 31, 2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.82%
Tags
earnings
News
Enanta Pharmaceuticals to Participate at the Oppenheimer 34th Annual Healthcare Life Sciences Conference
Rhea-AI Summary
Enanta Pharmaceuticals, Inc. (NASDAQ: ENTA) announced that its President and CEO, Jay R. Luly, Ph.D., and Chief Product Strategy Officer, Tara L. Kieffer, Ph.D., will participate in a fireside chat at the Oppenheimer 34th Annual Healthcare Life Sciences Conference on February 13, 2024. The event will be live webcast and accessible on the company's website. A replay will also be available for at least 30 days.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.37%
Tags
conferences
-
News
Enanta Pharmaceuticals to Host Conference Call on February 7 at 4:30 p.m. ET to Discuss its Financial Results for its Fiscal First Quarter Ended December 31, 2023
Rhea-AI Summary
Enanta Pharmaceuticals, Inc. (NASDAQ: ENTA) plans to report its fiscal first-quarter financial results on February 7, 2024, after the U.S. market closes. The company will host a conference call to discuss the results and provide an update on its business and research and development pipeline. A live webcast of the event will be accessible on Enanta's website. Participants can also join by phone and a replay of the webcast will be available for at least 30 days.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.41%
Tags
conferences earnings
-
News
Enanta Pharmaceuticals to Provide Updates on its Research and Development Programs and 2024 Outlook at the 42nd Annual J.P. Morgan Healthcare Conference
Rhea-AI Summary
Enanta Pharmaceuticals, a clinical-stage biotechnology company (NASDAQ:ENTA), announced expansion into immunology with a new discovery program of oral KIT inhibitors for Chronic Spontaneous Urticaria (CSU). They also expect topline data from at least one Phase 2 study of Zelicapavir (EDP-938), an N-Protein Inhibitor in development to treat Respiratory Syncytial Virus (RSV), in 3Q 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
13.8%
Tags
none
News
Enanta Pharmaceuticals to Present at the 42nd Annual J.P. Morgan Healthcare Conference
Rhea-AI Summary
Enanta Pharmaceuticals, Inc. (NASDAQ: ENTA) to present at 42nd Annual J.P. Morgan Healthcare Conference
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.96%
Tags
conferences
-
News
Enanta Pharmaceuticals to Participate at Evercore ISI HealthCONx Conference
Rhea-AI Summary
Enanta Pharmaceuticals, Inc. (ENTA) announced that its President and CEO, Dr. Jay R. Luly, will participate in a fireside chat at Evercore ISI HealthCONx Conference on November 29, 2023. The event will be live webcasted and accessible through the company's website. A replay will also be available for at least 30 days.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-9.83%
Tags
conferences
-
News
Enanta Pharmaceuticals Reports Financial Results for its Fiscal Fourth Quarter and Year Ended September 30, 2023, with Webcast and Conference Call Today at 4:30 p.m. ET
Rhea-AI Summary
Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) initiated a Phase 2a Challenge Study of EDP-323, an L-Protein Inhibitor, in Development as an Oral, Once-Daily Treatment for Respiratory Syncytial Virus (RSV). The company expects to report data in Q3 2024. Enanta also streamlined business and significantly lowered 2024 R&D and G&A spending guidance to support ongoing operations. Cash and Marketable Securities totaled $370 million at September 30, 2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
11.52%
Tags
earnings
News
Enanta Pharmaceuticals to Host Conference Call on November 20 at 4:30 p.m. ET to Discuss its Financial Results for its Fiscal Fourth Quarter and Full Year Ended September 30, 2023
Rhea-AI Summary
Enanta Pharmaceuticals, Inc. (NASDAQ: ENTA) to Report Q4 and Full Year 2023 Financial Results and Host Conference Call
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.97%
Tags
conferences earnings
Stock ENTA logo
Enanta Pharmaceuticals Inc

Nasdaq:ENTA

ENTA Rankings

#3503 Ranked by Market Cap
#5339 Ranked by Stock Gains
N/A Ranked by Dividends

ENTA Stock Data

348.02M
13.34M
6.1%
100.26%
12.97%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
US
Watertown

About ENTA

enanta pharmaceuticals is a research and development-focused biotechnology company that uses its robust chemistry-driven approach and drug discovery capabilities to create small molecule drugs for viral infections and liver diseases. enanta is discovering, and in some cases developing, novel inhibitors designed for use against the hepatitis c virus (hcv). these inhibitors include members of the direct acting antiviral (daa) inhibitor classes – protease (partnered with abbvie), ns5a, and nucleotide polymerase – as well as a host-targeted antiviral (hta) inhibitor class targeted against cyclophilin. enanta’s lead protease inhibitor, paritaprevir, is part of abbvie’s recently approved hcv treatment regimen. in addition, enanta has a preclinical program in non-alcoholic steatohepatitis, or nash, which is a condition that results in liver inflammation and damage caused by a buildup of fat in the liver. enanta pharmaceuticals is a public company with offices in watertown, ma.